Cargando…

Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review

Secondary immunodeficiency is observed in all patients with chronic lymphocytic leukemia (CLL) in varying degrees. The aim of the study was to review the available literature data on patients with CLL, with particular regard to the pathogenesis of the disease and the impact of humoral immunity defic...

Descripción completa

Detalles Bibliográficos
Autores principales: Grywalska, Ewelina, Zaborek, Monika, Łyczba, Jakub, Hrynkiewicz, Rafał, Bębnowska, Dominika, Becht, Rafał, Sosnowska-Pasiarska, Barbara, Smok-Kalwat, Jolanta, Pasiarski, Marcin, Góźdź, Stanisław, Roliński, Jacek, Niedźwiedzka-Rystwej, Paulina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693361/
https://www.ncbi.nlm.nih.gov/pubmed/33147729
http://dx.doi.org/10.3390/cells9112398
Descripción
Sumario:Secondary immunodeficiency is observed in all patients with chronic lymphocytic leukemia (CLL) in varying degrees. The aim of the study was to review the available literature data on patients with CLL, with particular regard to the pathogenesis of the disease and the impact of humoral immunity deficiency on the clinical and therapeutic approach. A systematic literature review was carried out by two independent authors who searched PubMed databases for studies published up to January 2020. Additionally, Google Scholar was used to evaluate search results and support manual research. The search resulted in 240 articles eligible for analysis. After all criteria and filters were applied, 22 studies were finally applied to the analysis. The data analysis showed that the clinical heterogeneity of CLL patients correlates with the diversity of molecular abnormalities determining the clinical picture of the disease, the analysis of which enables setting therapeutic targets. Additionally, in improving the therapeutic method, it is worth introducing supportive therapies with the use of vaccines, antibiotics and/or immunoglobins. Moreover, humoral immunodeficiency in CLL has a strong influence on the risk of infection in patients for whom infections are a major cause of morbidity and mortality.